Abstract
Celiac disease (CD) is a condition potentially impairing seroconversion against hepatitis B virus (HBV). Methods. We studied retrospectively 81 consecutive CD patients (24 M and 57 F) with a median (interquartile range, IQR) age of 10 (7) yr (range 2-30 yr) and 50 controls (26 M and 24 F) with a median (IQR) age 7 (7) yr (range 1-26 yr) who received a standard anti-HBV vaccination schedule at 3, 5 and 11 months of age. Subjects affected by autoimmune and neoplastic diseases or immunosuppressive treatment where excluded from the study.
Results: The median (IQR) interval from the last dose of vaccine was higher in CD patients as compared to controls [10 (7), range 2-29 yr vs. 6 (7), range 1-26 yr, p < 0.0001]. The median (IQR) age of gluten introduction was comparable in the two groups [6 (1), range 4-12 mo vs. 6 (1), range 5-11 mo]. The median (IQR) duration of gluten intake in the CD group was 3.5 (4.8) yr (range 0.2- 12.3 yr). A cut-point ≥ 10 mUI/ml for HbsAg title was considered to indicate seroconversion for HBV vaccination. 33/81 CD patients did not seroconverte compared to 10/50 controls (p < 0.05). The Odds ratio of a protective HbsAg title in CD subjects vs controls was 0.36 (95% CI, 0.16-0.83, p < 0.0001) and was not associated with gender, the interval from the last administration of the vaccine nor with the duration of gluten intake in CD patients.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pontari, S., Bedogni, G., Garotta, M. et al. 1452 Seroconversion Rates in Celiac Disease After Hbv Vaccination. Pediatr Res 68 (Suppl 1), 717 (2010). https://doi.org/10.1203/00006450-201011001-01452
Issue Date:
DOI: https://doi.org/10.1203/00006450-201011001-01452